Arrowhead Pharmaceuticals, Inc.
ARWR
$17.67
$0.321.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -29.60% | -100.00% | -- | -- | -94.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.60% | -100.00% | -- | -- | -94.32% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -29.60% | -100.00% | -- | -- | -94.32% |
| SG&A Expenses | 12.16% | 11.37% | 7.91% | 16.20% | 17.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.00% | 30.36% | 48.61% | 28.63% | 33.83% |
| Operating Income | -18.21% | -49.73% | -71.51% | -362.00% | -224.07% |
| Income Before Tax | -26.26% | -58.54% | -68.28% | -366.37% | -231.84% |
| Income Tax Expenses | 103.11% | -73.04% | -- | -- | -19,588.24% |
| Earnings from Continuing Operations | -29.43% | -56.14% | -67.08% | -366.37% | -223.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.09% | 110.18% | 170.06% | 69.77% | 416.87% |
| Net Income | -30.27% | -55.49% | -65.91% | -357.42% | -221.51% |
| EBIT | -18.21% | -49.73% | -71.51% | -362.00% | -224.07% |
| EBITDA | -18.06% | -50.45% | -72.35% | -339.34% | -235.36% |
| EPS Basic | -12.09% | -34.06% | -42.94% | -322.92% | -217.40% |
| Normalized Basic EPS | -9.70% | -35.80% | -43.37% | -318.41% | -224.07% |
| EPS Diluted | -12.10% | -34.06% | -43.44% | -326.67% | -217.95% |
| Normalized Diluted EPS | -9.70% | -35.80% | -43.37% | -321.24% | -224.07% |
| Average Basic Shares Outstanding | 16.23% | 15.99% | 16.07% | 15.48% | 1.30% |
| Average Diluted Shares Outstanding | 16.23% | 15.99% | 16.07% | 14.00% | 1.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
